|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
AU2728588A
(en)
|
1987-10-23 |
1989-05-23 |
Genetics Institute Inc. |
Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5866114A
(en)
|
1992-06-09 |
1999-02-02 |
Chiron Corporation |
Crystallization of M-CSFα
|
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
WO1999029345A1
(en)
|
1997-12-05 |
1999-06-17 |
La Jolla Institute For Experimental Medicine |
Inhibition of tumor growth by macrophage intervention
|
|
AU6366999A
(en)
|
1998-10-30 |
2000-05-22 |
Takeda Chemical Industries Ltd. |
Betacellulin protein-containing preparations
|
|
DE50002293D1
(de)
|
1999-10-28 |
2003-06-26 |
Hofbauer Reinhold |
Verwendung von csf-1-inhibitoren
|
|
WO2001034177A2
(en)
|
1999-11-08 |
2001-05-17 |
The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health |
Method of treating a viral infection using antagonists of macrophage colony stimulating factor
|
|
US7108852B2
(en)
|
2000-03-20 |
2006-09-19 |
Warner-Lambert Company Llc |
Methods of treating inflammation using antibodies to M-CSF
|
|
US7455836B2
(en)
|
2000-05-08 |
2008-11-25 |
The University Of Melbourne |
Method of treatment and agents useful for same
|
|
US6773895B2
(en)
|
2000-09-01 |
2004-08-10 |
Boehringer Ingelheim Pharma Kg |
Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
|
|
US7247618B2
(en)
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
|
CA2450793A1
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
CN1787837A
(zh)
|
2002-11-15 |
2006-06-14 |
希龙公司 |
防止和治疗癌转移以及与癌转移相关的骨质损失的方法
|
|
US7807389B2
(en)
|
2003-03-14 |
2010-10-05 |
University Of Rochester |
Methods and compositions related to joint inflammation diseases
|
|
ES2393555T3
(es)
|
2003-10-22 |
2012-12-26 |
Keck Graduate Institute |
Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide.
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
WO2005070447A2
(en)
|
2004-01-21 |
2005-08-04 |
Chiron Corporation |
M-csf muteins and uses thereof
|
|
AU2005245896A1
(en)
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
|
CA2574654C
(en)
|
2004-07-22 |
2014-02-18 |
Five Prime Therapeutics, Inc. |
Compositions and methods of use for mgd-csf in disease treatment
|
|
WO2006076288A2
(en)
|
2005-01-11 |
2006-07-20 |
Five Prime Therapeutics, Inc. |
Dna constructs for long-term expression of intravascularly injected naked dna
|
|
EP1841874B1
(en)
|
2005-01-27 |
2010-01-06 |
Five Prime Therapeutics, Inc. |
Leader sequences for directing secretion of polypeptides and methods for production thereof
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
JP2009515521A
(ja)
|
2005-11-10 |
2009-04-16 |
レセプター バイオロジックス， インコーポレイテッド |
レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
|
|
WO2007075933A2
(en)
|
2005-12-21 |
2007-07-05 |
Cell Signaling Technology, Inc. |
Translocation and mutant csf1r kinase in human leukemia
|
|
CA2634945A1
(en)
|
2005-12-22 |
2007-10-25 |
Novartis Ag |
Soluble human m-csf receptor and uses thereof
|
|
EP1984024A2
(en)
|
2006-01-05 |
2008-10-29 |
Novartis AG |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
|
DK2010528T3
(en)
|
2006-04-19 |
2018-01-15 |
Novartis Ag |
6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
|
|
WO2008061013A2
(en)
|
2006-11-10 |
2008-05-22 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
|
WO2008060610A2
(en)
|
2006-11-17 |
2008-05-22 |
Biogen Idec Ma Inc. |
Systemic administration of colony stimulating factors to treat amyloid associated disorders
|
|
DE602008004296D1
(de)
|
2007-02-14 |
2011-02-17 |
Vaccinex Inc |
Humanisierte anti-cd100-antikörper
|
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
BRPI0812159A2
(pt)
|
2007-05-21 |
2017-05-02 |
Novartis Ag |
inibidores de csf-1r, composições e métodos de uso
|
|
WO2008150383A1
(en)
|
2007-05-30 |
2008-12-11 |
Albert Einstein College Of Medicine Of Yeshiva University |
Csf-1r mutants
|
|
RS56743B1
(sr)
|
2007-08-21 |
2018-03-30 |
Amgen Inc |
Humani c-fms antigen vezujući proteini
|
|
US7981415B2
(en)
|
2007-09-07 |
2011-07-19 |
Cisthera, Inc. |
Humanized PAI-1 antibodies
|
|
US20100261679A1
(en)
|
2007-10-18 |
2010-10-14 |
James Sutton |
CSF-1R, Inhibitors, Compositions, and Methods of Use
|
|
AU2008318656A1
(en)
|
2007-10-31 |
2009-05-07 |
Janssen Pharmaceutica N.V. |
Biomarker for assessing response to FMS treatment
|
|
WO2009075344A1
(ja)
|
2007-12-12 |
2009-06-18 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
CN101970496B
(zh)
|
2008-03-14 |
2014-04-16 |
特朗斯吉有限公司 |
针对csf-1r的抗体
|
|
US8158636B2
(en)
|
2008-05-19 |
2012-04-17 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
US8119637B2
(en)
|
2008-06-10 |
2012-02-21 |
Plexxikon Inc. |
Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
|
|
US8183207B2
(en)
|
2008-11-26 |
2012-05-22 |
Five Prime Therapeutics, Inc. |
Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
|
|
US8080246B2
(en)
|
2008-11-26 |
2011-12-20 |
Five Prime Therapeutics, Inc. |
Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
|
|
ES2633317T3
(es)
|
2009-11-06 |
2017-09-20 |
Plexxikon, Inc. |
Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
|
|
EP2949670B1
(en)
|
2009-12-10 |
2019-02-27 |
F. Hoffmann-La Roche AG |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
KR101779630B1
(ko)
|
2009-12-21 |
2017-09-18 |
어레이 바이오파마 인크. |
ｃＦＭＳ 억제제로서 치환된 Ｎ-（１Ｈ-인다졸-４-일）이미다조［１,２-ａ］피리딘-３-카복사미드 화합물
|
|
JP5989547B2
(ja)
*
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
|
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
SMT201900074T1
(it)
|
2010-05-04 |
2019-02-28 |
Five Prime Therapeutics Inc |
Anticorpi che legano csf1r
|
|
WO2012082573A1
(en)
|
2010-12-13 |
2012-06-21 |
Novartis Ag |
Predictive methods and methods of treating arthritis using il-17 antagonists
|
|
AU2012324847B2
(en)
|
2011-10-21 |
2017-01-12 |
Transgene Sa |
Modulation of macrophage activation
|
|
CA2852800A1
(en)
|
2011-10-21 |
2013-04-25 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
CN106267210A
(zh)
*
|
2012-03-26 |
2017-01-04 |
日本化学药品株式会社 |
骨·软组织中产生的巨细胞性肿瘤或软骨肉瘤的预防或治疗剂
|
|
US20130302322A1
(en)
|
2012-05-11 |
2013-11-14 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
CN104684582A
(zh)
|
2012-08-31 |
2015-06-03 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|